Advancing responsible regenerative medicine through scientific evaluation, clinical oversight, and continuous improvement.
At QC Kinetix, we believe that responsible medical innovation requires more than the availability of advanced treatment options. It requires experienced physician leadership, rigorous evaluation of scientific evidence, careful assessment of medical technologies, and a commitment to understanding patient outcomes.
The QC Kinetix Medical Management Team (MMT) is a multidisciplinary, physician-led body that guides the medical aspects of the QC Kinetix network. Its physicians bring backgrounds in orthopedic surgery, sports medicine, family medicine, internal medicine, musculoskeletal care, and regenerative medicine. The team also examines emerging scientific literature, evaluates new treatment approaches, and reviews clinical outcomes data to identify opportunities for improvement.
Our guiding philosophy is that clinical decisions should be informed by the best available evidence, sound medical judgment, and the individual needs of each patient.
The QC Kinetix clinical leadership structure brings together physicians, scientific and technical advisors, and clinical operations professionals. These groups contribute complementary expertise to the evaluation, development, and implementation of clinical practices.
Clinical experience. Independent medical judgment. Collaborative leadership.
The physician members draw on their specialties to evaluate treatment protocols, assess new technologies, interpret emerging research, and review patient outcomes. Their varied perspectives encourage candid discussion of the benefits, limitations, and appropriateness of regenerative and nonsurgical musculoskeletal treatments.
Physician Members
Scientific and Technical Advisor
Theodore Sand, PhD
Biotechnology and Regenerative Medicine Senior Consultant
Evaluating the science and technology behind clinical care.
The MMT draws on expertise in biotechnology, laboratory science, device performance, regulatory compliance, and product quality to evaluate regenerative medicine technologies, biologic preparation systems, and emerging clinical innovations.
The MMT’s scientific and technical reviews address device specifications, preparation methodologies, platelet recovery and concentration, cellular characteristics, sterility considerations, manufacturer documentation, and the strength of available supporting evidence.
The purpose of this evaluation is to help ensure that clinical technology decisions are grounded in appropriate scientific and technical considerations.
Clinical Operations Leadership
Ginger Arntz, MSN, FNP-C
Connecting medical guidance with clinical practice.
Clinical operations connect physician leadership with clinicians across the network – communicating medical guidance, supporting provider education and procedural documentation, and integrating approved practices. It also reports back to medical leadership on workflows, training needs, and opportunities for quality improvement.
Medical decisions remain the responsibility of appropriately licensed healthcare professionals exercising independent clinical judgment.
The Medical Management Team evaluates the medical and scientific foundations of QC Kinetix’s clinical programs, while also assessing operational considerations.
Its work encompasses six interconnected areas of responsibility.
The MMT evaluates the protocols used across the network – including patient selection, treatment indications, procedural techniques, treatment sequencing, follow-up, and documentation – to confirm they remain consistent with current evidence, clinical experience, and appropriate medical standards, and refines them when new information warrants. Each local professional entity and treating clinician retains authority over clinical policies and individual care decisions—including whether guidance is appropriate for a patient.
The MMT reviews medical devices, preparation systems, and clinical technologies under consideration for use within the network.
Evaluations may include:
The MMT seeks to distinguish clinically meaningful technological advances from unsupported or inadequately substantiated product claims.
The MMT supports systematic review of patient-reported outcomes – such as changes in pain, physical function, and satisfaction – to identify trends and refine protocols and patient selection. The goal is not simply to measure outcomes, but to use them responsibly to improve care (see Clinical Outcomes and Continuous Improvement below).
Regenerative medicine is an evolving field. The MMT reviews published research on the treatments and technologies QC Kinetix uses or is considering, including platelet-rich plasma, plasma protein-based preparations, bone marrow-derived treatments, orthobiologics, image-guided interventions, and complementary nonsurgical technologies.
The team weighs study methodology, sample size, clinical relevance, reproducibility, and safety findings, recognizing that promising early results do not by themselves establish effectiveness.
The MMT reviews the medical aspects of clinical operations with a focus on patient safety and appropriate care – including patient eligibility, informed consent, procedural standards, documentation, product handling, adverse events, follow-up, and regulatory requirements.
The aim is consistent clinical standards that preserve the independent judgment of each treating professional.
The MMT supports ongoing education and collaboration across the network. Drawing on its members’ diverse backgrounds, the team shares emerging evidence, protocols, techniques, and practical clinical experience to promote informed decision-making and professional development.
The MMT evaluates the protocols used across the network – including patient selection, treatment indications, procedural techniques, treatment sequencing, follow-up, and documentation – to confirm they remain consistent with current evidence, clinical experience, and appropriate medical standards, and refines them when new information warrants. Each local professional entity and treating clinician retains authority over clinical policies and individual care decisions—including whether guidance is appropriate for a patient.
The MMT reviews medical devices, preparation systems, and clinical technologies under consideration for use within the network.
Evaluations may include:
The MMT seeks to distinguish clinically meaningful technological advances from unsupported or inadequately substantiated product claims.
The MMT supports systematic review of patient-reported outcomes – such as changes in pain, physical function, and satisfaction – to identify trends and refine protocols and patient selection. The goal is not simply to measure outcomes, but to use them responsibly to improve care (see Clinical Outcomes and Continuous Improvement below).
Regenerative medicine is an evolving field. The MMT reviews published research on the treatments and technologies QC Kinetix uses or is considering, including platelet-rich plasma, plasma protein-based preparations, bone marrow-derived treatments, orthobiologics, image-guided interventions, and complementary nonsurgical technologies.
The team weighs study methodology, sample size, clinical relevance, reproducibility, and safety findings, recognizing that promising early results do not by themselves establish effectiveness.
The MMT reviews the medical aspects of clinical operations with a focus on patient safety and appropriate care – including patient eligibility, informed consent, procedural standards, documentation, product handling, adverse events, follow-up, and regulatory requirements.
The aim is consistent clinical standards that preserve the independent judgment of each treating professional.
The MMT supports ongoing education and collaboration across the network. Drawing on its members’ diverse backgrounds, the team shares emerging evidence, protocols, techniques, and practical clinical experience to promote informed decision-making and professional development.
Scientific Evaluation Is an Ongoing Responsibility
Medical knowledge evolves, and any treatment or technology that looks promising today must remain open to critical evaluation as new evidence emerges. The team asks six questions of every clinical practice and innovation:
No single protocol, product, or technology is assumed to be a permanent or universal solution. Responsible innovation requires both openness to new possibilities and a willingness to question the evidence behind them.
Patient-reported outcomes offer valuable insight into changes in pain, physical function, satisfaction, and the experience of care over time. The MMT reviews and interprets this information to better understand treatment experiences and identify opportunities for improvement.
Meaningful patient measures
Evaluating patient-reported changes in pain, function, and other relevant aspects of musculoskeletal health.
Longitudinal follow-up
Examining outcomes at different time points to better understand patient-reported experiences beyond the immediate treatment period.
Clinical interpretation
Considering patient characteristics, treatment differences, follow-up rates, and other factors that may influence reported results.
Continuous improvement
Using findings to inform discussions about clinical protocols, patient selection, provider education, and future quality initiatives.
Transparency in Outcomes Reporting
Outcomes information must be presented in context. Observational data can offer useful insight, but cannot by themselves establish that a treatment caused an improvement; incomplete follow-up, selection bias, differences among patients, and the absence of randomized comparison groups all affect interpretation.
QC Kinetix distinguishes patient-reported observations from conclusions established through controlled clinical research.
Meaningful progress in regenerative medicine depends on physician leadership, careful evaluation, professional accountability, and a willingness to refine clinical practice as knowledge advances.
Through collaboration among physicians, scientific advisors, and clinical operations professionals, the QC Kinetix Medical Management Team is committed to responsible innovation, evidence-informed medicine, and continuous improvement in the care of patients with musculoskeletal conditions.
Our commitment is to responsible innovation, evidence-informed medicine, and continuous improvement in the care of patients with musculoskeletal conditions.
"(Required)" indicates required fields